XCE Tirzepatide LY3298176 5mg/Vial 99% Purity GLP-1/GIP Receptor Agonist for Research

XCE Tirzepatide (LY3298176) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for type 2 diabetes research. This compound demonstrates superior efficacy in glucose control and weight management compared to selective GLP-1 receptor agonists.

The XCE Tirzepatide formulation exhibits greater affinity for GIP receptors than GLP-1 receptors, with studies showing it effectively mimics natural GIP activity. This dual mechanism of action produces more significant reductions in hyperglycemia in research models.

Our XCE Tirzepatide is supplied as lyophilized white powder with guaranteed purity exceeding 99%, verified by HPLC analysis. Each vial contains precisely 5mg of active peptide compound for accurate dosing in research applications.

This product is intended solely for laboratory research purposes. Not for human or veterinary use. Researchers should handle all peptide compounds with appropriate safety precautions in controlled laboratory environments.